These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 2474882)
1. Management of urinary retention due to benign prostatic hyperplasia using luteinizing hormone-releasing hormone agonist. Schlegel PN; Brendler CB Urology; 1989 Aug; 34(2):69-72. PubMed ID: 2474882 [TBL] [Abstract][Full Text] [Related]
2. Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy. Gabrilove JL; Levine AC; Kirschenbaum A; Droller M J Clin Endocrinol Metab; 1987 Jun; 64(6):1331-3. PubMed ID: 2437142 [TBL] [Abstract][Full Text] [Related]
3. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. Peters CA; Walsh PC N Engl J Med; 1987 Sep; 317(10):599-604. PubMed ID: 2441256 [TBL] [Abstract][Full Text] [Related]
4. Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. Gabrilove JL; Levine AC; Kirschenbaum A; Droller M J Clin Endocrinol Metab; 1989 Sep; 69(3):629-32. PubMed ID: 2474565 [TBL] [Abstract][Full Text] [Related]
5. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819 [TBL] [Abstract][Full Text] [Related]
6. Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy. Levine AC; Kirschenbaum A; Droller M; Gabrilove JL J Urol; 1991 Sep; 146(3):790-3. PubMed ID: 1714969 [TBL] [Abstract][Full Text] [Related]
7. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. Eri LM; Tveter KJ J Urol; 1993 Aug; 150(2 Pt 1):359-64. PubMed ID: 7686981 [TBL] [Abstract][Full Text] [Related]
8. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride. Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474 [TBL] [Abstract][Full Text] [Related]
9. Endocrine and clinical effects of leuprolide in prostatic cancer. Vance MA; Smith JA Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399 [TBL] [Abstract][Full Text] [Related]
10. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690 [TBL] [Abstract][Full Text] [Related]
12. Can prostate epithelial content predict response to hormonal treatment of patients with benign prostatic hyperplasia? Eri LM; Svindland A Urology; 2000 Aug; 56(2):261-5. PubMed ID: 10925090 [TBL] [Abstract][Full Text] [Related]
13. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. Weber JP; Oesterling JE; Peters CA; Partin AW; Chan DW; Walsh PC J Urol; 1989 Apr; 141(4):987-92. PubMed ID: 2467015 [TBL] [Abstract][Full Text] [Related]
14. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia. Eri LM; Haug E; Tveter KJ Scand J Clin Lab Invest; 1996 Jul; 56(4):319-25. PubMed ID: 8837238 [TBL] [Abstract][Full Text] [Related]
15. Effect of LH-RH analogue in patients with benign prostatic hyperplasia. Lukkarinen O Urology; 1991 Feb; 37(2):92-4. PubMed ID: 1704161 [TBL] [Abstract][Full Text] [Related]
18. Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia. Eri LM; Tveter KJ J Urol; 1994 Aug; 152(2 Pt 1):448-52. PubMed ID: 7516978 [TBL] [Abstract][Full Text] [Related]
19. Treatment of benign prostatic hypertrophy by a long-acting gonadotropin-releasing hormone analogue: 1-year experience. Matzkin H; Chen J; Lewysohn O; Braf Z J Urol; 1991 Feb; 145(2):309-12. PubMed ID: 1703239 [TBL] [Abstract][Full Text] [Related]
20. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Debruyne F; Tzvetkov M; Altarac S; Geavlete PA Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]